Analyst Research

Report Title Price
Provider : ValuEngine, Inc.
$25.00
Provider : Stock Traders Daily
$20.00
Provider : Stock Traders Daily
$20.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Bristol-Myers Squibb Co and Pfizer announces U.S. FDA approves Eliquis (apixaban)


Thursday, 21 Aug 2014 01:31pm EDT 

Bristol-Myers Squibb Co and Pfizer:Says U.S. Food and Drug Administration (FDA) has approves Supplemental New Drug Application (sNDA) for Eliquis for treatment of DVT and PE, and for reduction in risk of recurrent DVT and PE following initial therapy.Combined, DVT and PE are known as VTE.It is estimated that every year, about 900,000 Americans are affected by DVT and PE. 

Company Quote

60.61
-0.21 -0.35%
28 Aug 2015